Brandon Folkes, an analyst from H.C. Wainwright, maintained the Buy rating on Omeros. The associated price target remains the same with $9.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Folkes has given his Buy rating due to a combination of factors surrounding Omeros’s potential market opportunity with Narsoplimab. The recent study published in the American Journal of Hematology highlights significant concerns regarding the use of eculizumab in pediatric patients with thrombotic microangiopathy following hematopoietic cell transplantation. This study found that eculizumab is associated with increased infection rates and infection-related mortality, which positions Narsoplimab as a potentially safer alternative if approved.
Folkes believes that the findings from this study could serve as a catalyst for Narsoplimab’s uptake, as it validates the clinical and commercial rationale for choosing Narsoplimab over eculizumab in treating TA-TMA patients. The study’s results underscore the potential advantages of Narsoplimab, which could lead to higher than anticipated market adoption and drive Omeros’s stock performance positively.